Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR

Am Heart J. 2015 Jul;170(1):173-9, 179.e1. doi: 10.1016/j.ahj.2015.04.021. Epub 2015 Apr 24.

Abstract

Background: Understanding risk factor burden and control as well as perceived risk prior to acute myocardial infarction (MI) presentation may identify gaps in contemporary systems of care.

Methods: Patients presenting with MI in the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines between January 2007 and November 2013 (N = 443,117) were stratified into 5 mutually exclusive risk categories: Framingham Risk Score (FRS) <10% 74,990 (16.9%), FRS 10% to 20% 90,429 (20.4%), FRS >20% 25,701 (5.8%), diabetes without cardiovascular disease (CVD) 67,779 (15.3%), and prior CVD 184,218 (41.6%). Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol (non-HDL-C) goals and statin eligibility were determined based on the Third Adult Treatment Panel.

Results: At presentation, 66.3% met the low-density lipoprotein cholesterol goal, 66.8% met the non-HDL-C goal, 63.7% were nonsmokers, and 65.1% of patients with prior CVD were on aspirin. Only 36.1% of patients met all assessed risk factor control metrics. Overall statin eligibility prior to MI was 60.8%, and 61.1% of statin-eligible patients reported statin use.

Conclusion: Risk factor control prior to MI was suboptimal, with the majority of individuals failing to meet at least 1 risk factor control metric. More effective system-based interventions are needed to promote adherence to prevention targets.

MeSH terms

  • Aged
  • Aspirin / therapeutic use
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / epidemiology
  • Diabetes Mellitus / epidemiology*
  • Dyslipidemias / drug therapy
  • Dyslipidemias / epidemiology*
  • Female
  • Guideline Adherence / statistics & numerical data*
  • Hospitalization*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Male
  • Middle Aged
  • Myocardial Infarction / epidemiology*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Practice Guidelines as Topic*
  • Risk Factors
  • Smoking / epidemiology*
  • United States / epidemiology

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors
  • Aspirin